CONGRESS: 22–25 SEPTEMBER 2025
Biosystem’s histopathology testing and Cepheid’s fast molecular testing combine to provide a complete picture of a tissue or disease and improve diagnostic confidence. This is especially valuable in oncology, where integrating Cepheid’s mutation testing with Leica’s histopathological findings can help to accelerate treatment for cancers – improving patient outcomes and aligning with NHS targets for faster cancer diagnosis.
Radiometer.
Unified diagnostic continuum Each of these Danaher companies delivers unique strengths that combine to span the full patient journey. n Radiometer provides POC solutions that support urgent and acute care settings with blood gas and immunoassay analysers, delivering vital parameters in seconds. The company’s scalable, vendor-neutral IT middleware, AQURE, provides a comprehensive overview of all POC devices, real-time device and operator management, reports, interfacing with hospital systems, helping with accreditation and compliance requirements.
n Cepheid has a pioneering approach to molecular diagnostics, which facilitates testing everywhere. Its fast PCR tests deliver accurate results for infectious diseases, antimicrobial resistance (AMR), and oncology markers, with results from 30 minutes to just a few hours, expediting early and targeted treatment, and improved patient flow.
n Leica Biosystems specialises in anatomical pathology, offering end-to- end workflows from biopsy and tissue processing to digital slide scanning. Its digital histopathology solutions enable pathologists to diagnose cancer and other diseases more efficiently, with support from automated image analysis tools and remote collaboration platforms.
Together, they form a complete diagnostic continuum – from rapid triage to molecular testing and tissue- level insights, across both POC and central laboratory settings, supporting clinicians and infection prevention and control teams with timely, high-quality results wherever care is delivered. This combined approach simplifies complexity and minimises human error, shortens
turnaround times, and enables better clinical decision-making.
Building connected diagnostic pathways in practice The benefits of the natural synergies between these companies that span multiple disciplines and technologies can be found, for example, in a pathway where a patient presents with respiratory distress. n Initial triage testing is undertaken using Radiometer solutions to obtain POC blood gas and lactate results to quickly assess the patient’s critical physiological status.
n A fast Cepheid respiratory or healthcare-associated infection PCR test can then identify multiple viral and bacterial pathogens, including resistance genes to support antimicrobial stewardship and infection control.
n Leica Biosystems is used to rapidly analyse a follow-up biopsy using digital histopathology to rule out malignancy.
In the UK, there are multiple examples of where a collaborative approach between these three distinct technologies is being used. In one NHS trust, Cepheid’s rapid respiratory PCR testing panel is combined with Radiometer’s POC blood gas analysis, including U&Es (eGFR), which enables faster triage to improve patient flow during winter pressures. At the Queen Alexandra Hospital in Portsmouth, the ability to integrate data from Cepheid’s GeneXpert system with Touchscreen using Radiometer’s AQURE vendor-neutral IT middleware enables centralised connectivity across the POC network and helps to deliver simplified workflows.
Another example of these synergies supporting connected diagnostic pathways is found where Leica
WWW.PATHOLOGYINPRACTICE.COM AUGUST 2025
Such multi-dimensional diagnostic insights offered by the combined Danaher Diagnostics Solution enhance diagnostic confidence, support targeted therapy, reduce the likelihood of repeat testing or missed information, and shorten turnaround times.
Operational and economic efficiencies
Customers working with Danaher Diagnostic’s ecosystem can gain further benefits from an operational perspective. The Danaher managed service offering provides a cohesive partnership to meet objectives and strategic goals. This includes: n comprehensive support for managing POC
n customised solutions n flexibility and agility n contract performance n risk management n quality assurance n efficiency n innovation.
Conclusions Traditionally, diagnostic tests are spread across multiple departments and systems – acute care testing, molecular diagnostics, and anatomical pathology often operating in siloes. This can lead to duplication, delays, and the potential for miscommunication. By integrating these diagnostic disciplines, Danaher’s approach through Radiometer, Cepheid, and Leica Biosystems offers a powerful remedy.
For customers, this continuum of integrated and interoperable solutions helps to meet the demands of modern clinical diagnostics, translating into improved workflow efficiencies, enhanced diagnostics confidence, and ultimately improved patient outcomes.
Find out more in person about the benefits of end-to-end diagnostics workflows delivered by Danaher Diagnostics Solutions on Stand 109 and also Beckman Coulter’s Stand 608 at IBMS Congress 2025.
www.radiometer.co.uk www.cepheid.com
www.leicabiosystems.com/en-gb/
47
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72
